Table 3: Alogliptin-induced changes in apoprotein and predictive markers for the onset risk of cardiovascular events

Before administration After administration P value
ApoB 91.0 ± 16.4 mg/dL
(0.91 ± 0.16 g/L)
85.0 ± 14.0 mg/dL
(0.85 ± 0.14 g/L)
p< 0.01
ApoA-1 153.1 ± 27.4 mg/dL
(1.53 ± 0.27 g/L)
153.9 ± 28.1 mg/dL
(1.54 ± 0.28 g/L)
NS
ApoB/ApoA-1 0.61 ± 0.15 0.57 ± 0.12 P< 0.05
LDL/ApoB 1.16 ± 0.11 1.20 ± 0.13 P< 0.01